Long-term @entity8633 monotherapy for XXXX .

@entity1 @entity1242 @entity8633 @entity951 @entity943
The long-term efficacy of @entity8633 as once-a-day monotherapy was studied in 19 @entity1 with stable @entity951 . After 2 weeks of single-blind placebo therapy and a 12-week parallel placebo-controlled, dose-response study, each @entity1 received open-label @entity8633 . After a dose-titration period of 3 months, @entity1 received @entity8633 (100 to 400 mg once a day, mean 290 mg) for 24 months. The response to treatment was assessed by @entity1 diaries and serial treadmill exercise testing 24 hours after dose administration, every 3 months. Only 2 @entity1 were released from the study due to therapeutic failure. Compared with placebo, 3 months of @entity8633 therapy resulted in a significant reduction in the weekly frequency of angina from 10.3 +/- 9.1 to 1.8 +/- 3.5 (p less than 0.002) and @entity1242 consumption from 5.0 +/- 5.4 to 1.4 +/- 2.3 (p less than 0.01). In addition, there was a simultaneous significant increase in the walking time to angina from 5.2 +/- 2.3 to 7.9 +/- 2.6 minutes (p less than 0.001) and total exercise time from 7.1 +/- 2.2 to 8.8 +/- 1.9 minutes (p less than 0.001). These favorable effects were sustained throughout the 24 months of the study. Although resting QTc interval was prolonged by 36 to 42 ms (p less than 0.001) during @entity8633 therapy, @entity943 were not observed immediately before or during exercise testing and were not manifested by symptoms. Neurologic and gastrointestinal side effects of mild to moderate severity were observed, but none required discontinuation of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
